Key result
Dabigatran provides an AF stroke prevention alternative to VKAs, but key monitoring and safety concerns persist.
Why the study?
Dabigatran is introduced for stroke prevention in atrial fibrillation despite many unresolved issues regarding monitoring, use in elderly and renal insufficiency, interactions, and lack of antidote.
Answers are grounded in this paper and cite their sources.
Unresolved monitoring, safety, and antidote concerns with dabigatran in AF warrant clinical caution in vulnerable patients; challenges consensus favoring its use over vitamin K antagonists.
Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients. Dabigatran is introduced into clinical practice, although many issues regarding this drug are still unclear, like laboratory monitoring, use in elderly patients, drug- and food-interactions and use in patients with renal insufficiency. Additionally, there is no antidote for dabigatran. Thus, aim of the present review is to give an overview of concerns and unresolved issues concerning dabigatran.
No takes yet. Share an insight, caveat, or question.
Stöllberger et al. (2012) conducted a review in Atrial fibrillation. Dabigatran vs. Vitamin K antagonists (e.g., Warfarin) was evaluated. Dabigatran is used as an alternative to vitamin K antagonists for stroke prevention in atrial fibrillation, but unresolved clinical concerns remain regarding laboratory monitoring, safety in the elderly and renally impaired, and the lack of a specific antidote.
Synapse has enriched 10 related papers. Consider them for comparative context: